液體活檢在肺癌早期診斷中的應(yīng)用研究進(jìn)展

打開文本圖片集

［摘要］液體活檢是肺癌診斷的一種重要方法，較之傳統(tǒng)組織活檢，有安全無創(chuàng)、標(biāo)本易獲取、可動態(tài)監(jiān)測等優(yōu)勢，在早期肺癌診斷中有確切價值。本文總結(jié)國內(nèi)外液體活檢診斷早期肺癌的研究進(jìn)展，探討其在早期肺癌診斷中的價值。

［關(guān)鍵詞］液體活組織檢查；肺腫瘤；早期診斷；生物標(biāo)記，腫瘤；綜述

［中圖分類號］R734.2;R446.8［文獻(xiàn)標(biāo)志碼］A［文章編號］2096-5532（2024）03-0470-05

doi：10.11712/jms.2096-5532.2024.60.106［開放科學(xué)（資源服務(wù)）標(biāo)識碼（OSID）］

［網(wǎng)絡(luò)出版］https：//link.cnki.net/urlid/37.1517.R.20240730.1145.003;2024-07-3109：16：33

Research advances in the application of liquid biopsy in the diagnosis of early-stage lung cancerHUANG Tongtong， XIN Ying， YIN Xiaojiao， SUN Yanqiu， XU Tao（Department of Respiratory and Critical Care Medicine， The Affiliated Hospital of Qing-dao University， Qingdao 266000， China）

［Abstract］Liquid biopsy is an important method for the diagnosis of lung cancer， and compared with traditional tissue biopsy， liquid biopsy has the advantages of favorable safety， noninvasiveness， convenience in obtaining specimens， and dynamic monitoring. Therefore， it has a marked value in the diagnosis of early-stage lung cancer. This article summarizes the research advances in liquid biopsy in the diagnosis of early-stage lung cancer in China and globally and discusses its value in the diagnosis of early-stage lung cancer.

［Key words］liquid biopsy; lung neoplasms; early diagnosis; biomarkers， tumor; review

肺癌是世界范圍內(nèi)發(fā)病率及病死率最高的惡性腫瘤之一， 據(jù)美國癌癥協(xié)會統(tǒng)計，2020年全球肺癌新增病例和新增死亡病例在所有癌癥中的占比分別是11.4%和18.0%[1]。（剩余13515字）